SCHEMBL6925514

SCHEMBL6925514

CCN(CC)CCOc1cccc2c1c1cc(C)ccc1n2Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.48
DRD2 P14416 2/20 0.46
DRD3 P35462 2/20 0.46
DRD1 P21728 1/20 0.46
ESR1 P03372 3/20 0.43
KMT2A Q03164 3/20 0.42
LMNA P02545 2/20 0.42
ESR2 Q92731 2/20 0.42
PLA2G2A P14555 2/20 0.41
HTR6 P50406 2/20 0.41
MAPT P10636 2/20 0.40
MEN1 O00255 2/20 0.40
CYP1A2 P05177 1/20 0.40
LTA4H P09960 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
POLB P06746 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6924126 0.92 ESR1 (0.43) MAPK1DRD2DRD3DRD1ESR1
SCHEMBL6927241 0.90 DRD2 (0.51) DRD2DRD3DRD1ESR1KMT2A
SCHEMBL6927808 0.89 DRD2 (0.46) DRD2DRD3DRD1ESR1KMT2A
SCHEMBL6919998 0.89 MEN1 (0.49) DRD2DRD3DRD1ESR1KMT2A
SCHEMBL6923328 0.86 PLA2G2A (0.45) KMT2ALMNAPLA2G2AHTR6MAPT
SCHEMBL6926722 0.84 HTR6 (0.48) KMT2ALMNAPLA2G2AHTR6HTR1D
SCHEMBL6920875 0.84 MEN1 (0.43) DRD2DRD3DRD1ESR1KMT2A
SCHEMBL6923520 0.83 MAPK1 (0.46) MAPK1DRD2DRD3DRD1ESR1
SCHEMBL6924596 0.83 DRD2 (0.49) DRD2DRD3DRD1ESR1KMT2A
SCHEMBL6928709 0.82 HTR1B (0.46) DRD2DRD3DRD1ESR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US claimed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP claimed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO claimed
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US disclosed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP disclosed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO disclosed